EPLAW PATENT BLOG

UK – Illumina v. Premaitha

Posted: December 23rd, 2017

Illumina v Premaitha, UK Patents Court, Carr J, 21 November 2017 Illumina has succeeded in a claim that a non-invasive prenatal diagnosis test offered by Premaitha infringed five related patents and that a gender testing component of an Ariosa Diagnostics product infringed a further patent. This lengthy, yet insightful judgement is effectively three judgments in […]

READ MORE

DK – ELI LILLY V. FRESENIUS KABI (PEMETREXED)

Posted: December 22nd, 2017

Eli Lilly and Company and Eli Lilly Danmark A/S (“Lilly”) v. Fresenius Kabi AB v/Fresenius Kabi and Fresenius Kabi Oncology Plc. (“Fresenius Kabi”), the Danish Maritime and Commercial High Court, Case number A-19-17, 8 December 2017 The case concerns the infringement of Lilly’s patent DK/EP 1 313 508 (“DK/EP ‘508”) which relates to the use […]

READ MORE

NO – Orifarm v. Mundipharma

Posted: November 24th, 2017

Orifarm Generics AS et al. v. Mundipharma AS, Oslo District Court, Norway, Joint cases 16-135025TVI-OTIR/01 and 16-141308TVI-OTIR/01, 8. September 2017 On 8 September 2017, Oslo District Court rendered its decision in a case uniting two separate cases between Orifarm and Mundipharma (patentee) regarding claims of infringement and invalidity of Mundipharma’s patents NO 334290, 332248 and […]

READ MORE

NL – MSD v. Teva / Supreme Court – indirect infringement of Swiss type claims

Posted: November 14th, 2017

Merck Sharp & Dohme Corp. v. Teva Pharma B.V. and Pharmachemie B.V., Supreme Court of The Netherlands, The Hague, 3 November 2017, Case no ECLI:NL:HR:2017:2807 The Supreme Court holds that indirect infringement of a Swiss type claim is possible. A Swiss-type claim is in the form of a purpose bound method claim. If such a […]

READ MORE

NL – Sandoz v. Astrazeneca / Appeal

Posted: November 2nd, 2017

Sandoz B.V. v. Astrazeneca AB, Court of Appeal The Hague, The Netherlands, 31 October 2017, Case No. 200.200.332/01, with thanks to Willem Hoyng and Theo Blomme, HOYNG ROKH MONEGIER, for submitting the case including an English and German translation thereof Astrazeneca markets FASLODEX which is used for the treatment of oestrogen hormone dependent breast cancers. […]

READ MORE

CH – Eli Lilly v. Actavis / Swiss Federal Supreme Court (Pemetrexed)

Posted: November 1st, 2017

On 20 October 2017, the Swiss Federal Supreme Court handed down its decision in Eli Lilly vs. Actavis re infringement of Eli Lilly’s patent EP 1 313 508 regarding the use of the anti-cancer drug, pemetrexed in combination with a vitamin B12 to alleviate the harmful side-effects of the drug. In its decision, the Court […]

READ MORE

NL – Eli Lilly and Company v. Fresnius Kabi and Teva (Pemetrexed)

Posted: October 31st, 2017

Eli Lilly and Company v. Fresenius Kabi Nederland B.V., Preliminary Relief Judge District Court of The Hague, the Netherlands, 24 October 2017, Case number C/09/537158 / KG ZA 17/1072 Eli Lilly and Company v. Teva Nederland B.V., Preliminary Relief Judge District Court of The Hague, the Netherlands, 24 October 2017, Case number C/09/538525 / KG […]

READ MORE

IT – Fresenius v. Lilly

Posted: October 3rd, 2017

Fresenius Kabi Oncology PLC and Fresenius Kabi Italia S.r.l. (“Fresenius”) sought before the Court of Milan a urgent declaration of non-infringement with respect to their new antitumor drug based on pemetrexed diacid in combination with tromethamine. Fresenius requested the Court to declare that its drug does not infringe – whether directly or indirectly – EP […]

READ MORE

NL – Asetek v. Cooler Master Europe

Posted: September 29th, 2017

Asetek A/S v. Cooler Master Europe B.V., District Court of The Hague, the Netherlands, 20 September 2017, Case number C/09/515892 / HA ZA 16-906 Asetek is the holder of the European patent EP 1 923 771 B1 (“EP ‘771”) entitled “Cooling system for a computer system”. The patent was filed on 8 November 2004 relying […]

READ MORE